Known as mono and the “kissing disease,” infectious mononucleosis is highly contagious and most commonly transmitted through saliva – sharing drinks or kissing someone who is infected. Epstein-Barr virus (EBV) is the most common cause of infectious mononucleosis, yet other viruses can also cause this condition. Symptoms usually appear four to six weeks after infection with EBV, may develop slowly and are known to last for weeks to several months following infection. Mono is most common among teenagers and young adults – at least one out of four1 will get infected with EBV and develop mono.
“The severe fatigue and malaise associated with mono can last for weeks and can be debilitating for some, leading to hospitalization and prolonged absence from work or school. If left untreated, mono can also lead to complications like liver inflammation and enlarged spleen2,” said renowned natural health physician and best-selling author, Dr. Fred Pescatore. “There are no known antibiotics or prescriptions to specifically treat mono. This research on Robuvit® provides promising, measurable results for mono patients.”
The new study examined a group of 50 participants who opted into either the test group for Robuvit® supplementation or a control group following standard management practices.
Each of these participants tested positive for EBV indicating mono and began their standard management regimen, which included healthy diet, exercise and supplementation with small amounts of zinc and copper, and supplementation with Robuvit®. Researchers evaluated participant symptoms based on the Karnofsky Performance Scale Index (KPSI), which classifies patients according to their functional impairment and fatigue. Participants in the Robuvit® test group supplemented with 300 mg of Robuvit® daily for four weeks and reported improvements in most major symptoms of mono, including:
- 87 percent of participants reported were free of mono-related fatigue (vs 69 percent in the control group)
- 92 percent of participants were free of malaise (vs 73 percent in the control group)
- 92 percent of participants were free of long-lasting symptoms (vs 65 percent rin the control group)
- 62 percent of participants tested negative for swollen nodes in ultrasound exams (vs 38 percent in the control group)
In the study, those who supplemented with Robuvit® shortened their absence from work or school as a result of their mono illness by 4.2 days compared to the control group which missed 7 days, on average. Moreover, researchers found that oxidative stress levels in the Robuvit® test group were normalized in 83 percent of the participants.
“This research shows the ability of Robuvit® to cut the duration of symptoms and to combat the nagging fatigue that lingers for mono patients. Several studies show Robuvit® is a natural energy booster and fatigue-fighter. This study showed that consistent performance even with a condition that is known for its lingering fatigue symptoms,” said Dr. Pescatore.
Robuvit® French oak wood extract is a powerful natural antioxidant shown to support natural energy and combat the effects of both general fatigue and chronic fatigue syndrome (CFS). This new study builds off of the body of research showing Robuvit®‘s benefits for natural caffeine-free energy.
To review clinical research and additional information on Robuvit®, visit www.robuvit.com.
About Horphag Research (USA) Inc.
Horphag Research (USA) Inc., based in Hoboken, New Jersey, is the North American distributor for Pycnogenol® (pic-noj-en-all) brand French maritime pine bark extract and Robuvit®, French oak wood extract on behalf of Horphag Research. Pycnogenol® and Robuvit® are registered trademarks of Horphag Research Ltd. Robuvit® was awarded Ingredient of the Year for Sport & Energy at Nutraingredients Awards 2017. For its patented ingredient, Pycnogenol®, Horphag Research has been awarded the Frost & Sullivan Excellence in Research Award, Nutraceutical Business & Technology Safety & Quality Award, SupplySide West Scientific Excellence Award and The American Botanical Council’s Tyler Research Award. Horphag Research (USA) has the exclusive rights to market and sell Pycnogenol® in North America and benefits from more than 40 years of scientific research assuring the safety and efficacy of Pycnogenol® as a dietary supplement. For more information, visit www.pycnogenol.com and www.Robuvit.com.